3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
3
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Colorectal Neoplasms
28
Stomach Neoplasms
21
Pancreatic Neoplasms
14
Colonic Neoplasms
14
Rectal Neoplasms
9
Esophageal Neoplasms
8
Lymphoma, Large B-Cell, Diffuse
7
Adenocarcinoma Of Esophagus
7
Neoplasms
6
Carcinoma, Non-Small-Cell Lung
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Cholangiocarcinoma
4
Adenocarcinoma
4
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Esophageal Squamous Cell Carcinoma
3
Squamous Cell Carcinoma of Head and Neck
2
Lymphoma, Follicular
2
Hepatoblastoma
2
Gastrointestinal Neoplasms
2
Gallbladder Neoplasms
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Unresectable Colorectal Cancer
1
Triple Negative Breast Neoplasms
1
Spinocerebellar Degenerations
1
Solid Cancer
1
Skin Neoplasms
1
Recurrence
1
Interventions
Rituximab
13
Cyclophosphamide
10
Lenalidomide
8
venetoclax
5
ibrutinib
5
fludarabine
4
CT-P10
4
orelabrutinib
3
obinutuzumab
3
fludarabine phosphate
3
Vincristine
3
tafasitamab
2
pirtobrutinib
2
copanlisib
2
acalabrutinib
2
Whole-Body Irradiation
2
Tacrolimus
2
Specimen Handling
2
Prednisone
2
Nivolumab
2
Mycophenolic Acid
2
Melphalan
2
Magnetic Resonance Spectroscopy
2
Hyaluronoglucosaminidase
2
Etoposide
2
Doxorubicin
2
Busulfan
2
Bendamustine Hydrochloride
2
selinexor
1
prednylidene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Lymphoma, B-Cell, Marginal Zone
×
Oxaliplatin
×
Clear all
NCT04542824
2026-06-02
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2
Active not recruiting
78 enrolled